TrialDiabetes care2015

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

William T Cefalu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.